Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06060041 · ClinicalTrials.gov registry record

IC-8 Apthera IOL New Enrollment Post Approval Study

A clinical trial of Cataract and Presbyopia, sponsored by Bausch & Lomb Incorporated.

Recruiting
Registry status
435
Enrollment target
14
Study locations

NCT06060041 is a study of Cataract and Presbyopia that is actively recruiting participants, run by Bausch & Lomb Incorporated. The registered enrollment target is 435 participants, above the 223-participant average among 83 other Cataract trials with a reported enrollment target (95% higher). The trial reports 14 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06060041, a study of Cataract and Presbyopia, is actively recruiting participants, sponsored by Bausch & Lomb Incorporated.

RECRUITING
Registry status
435 participants
Enrollment target
14
Study locations

Study Summary

The purpose of this study is to verify the post-market safety of the IC-8 Apthera IOL after the treatment of posterior capsular opacification (PCO), an expected complication related to IC-8 Apthera IOL implantation.

Study Locations (14)

Florida

  • Argus Research Center - Cape Coral
  • Stephenson Eye Associates - Venice

New Jersey

  • Eye Associates of New Jersey - Dover
  • Northern New Jersey Eye Institute - South Orange

Alabama

  • Trinity Research Group, LLC - Dothan

California

  • Feinerman Vision Center - Newport Beach

Illinois

  • Virdi Eye Clinic and Laser Vision Center - Rock Island

Indiana

  • Price Vision Group - Indianapolis

Kansas

  • Grene Vision Group - Wichita

Michigan

  • Oakland Eye - Birmingham

Trial Details

FieldValue
Enrollment Target 435 participants
Start Date 2023-09-08
Est. Completion 2027-09-30

Sponsor

Bausch & Lomb Incorporated

174 total trials

What the Registry Record Tells You About NCT06060041

The ClinicalTrials.gov registry entry for NCT06060041 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 435 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 223-participant average among 83 other Cataract trials with a reported enrollment target (95% higher). The listed sponsor is Bausch & Lomb Incorporated, which has 174 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Cataract appearing as the primary indexed condition, and to 0 interventions.

NCT06060041 reports 14 study locations spanning 12 distinct geographic areas - top geographies include Florida, New Jersey, Alabama.

Frequently Asked Questions

What is clinical trial NCT06060041 about?

NCT06060041 is a clinical study titled "IC-8 Apthera IOL New Enrollment Post Approval Study". The purpose of this study is to verify the post-market safety of the IC-8 Apthera IOL after the treatment of posterior capsular opacification (PCO), an expected complication related to IC-8 Apthera IOL implantation.

What is the current status of trial NCT06060041?

This trial is currently recruiting. The enrollment target is 435 participants. The study started on 2023-09-08. Estimated completion is 2027-09-30.

What conditions does trial NCT06060041 study?

This clinical trial studies the following conditions: Cataract, Presbyopia, Posterior Capsule Opacification.

Who is sponsoring clinical trial NCT06060041?

This trial is sponsored by Bausch & Lomb Incorporated, which has 174 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06060041 being conducted?

This trial has 14 study locations across Alabama, California, Florida, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cataract

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.